In-hospital treatment and procedures in patients with cardiogenic shock managed in hospitals with versus those without catheterisation facilities
| Facilities (n=186) | No facilities (n=68) | p Value | |
| Drugs | |||
| Aspirin | 101 (54%) | 31 (46%) | 0.22 |
| Digoxin | 37 (20%) | 12 (18%) | 0.69 |
| Nitrates | 96 (52%) | 33 (49%) | 0.66 |
| ACE inhibitors | 54 (29%) | 14 (21%) | 0.18 |
| β Blockers | 30 (16%) | 7 (10%) | 0.24 |
| Amiodarone | 9 (5%) | 2 (3%) | 0.51 |
| Abciximab (ReoPro) | 4 (2%) | 0 (0%) | 0.22 |
| Thrombolysis | 56 (30%) | 26 (38%) | 0.22 |
| Angiography | 49 (26%) | 3 (4%) | < 0.001 |
| PTCA | 39 (21%) | 3 (4%) | 0.001 |
| Primary PTCA | 34 (87%) | 2 (66%) | 0.05 |
| Successful PTCA | 31/39 (80%) | 2/3 (67%) | 0.60 |
| Time from shock (h) | < 0.001 | ||
| Median | 0 | 0 | |
| 25th–75th centile | 0–0 | 0–3 | |
| IABP | 52 (28%) | 3 (4%) | < 0.001 |
| CABG | 8 (4%) | 1 (1%) | 0.28 |
Values are n (%).
ACE, angiotensin converting enzyme; CABG, coronary artery bypass graft; IABP, intra-aortic balloon pump; PTCA, percutaneous transluminal coronary angioplasty.